DiaMedica Therapeutics Stock (NASDAQ:DMAC)


ForecastRevenueOwnershipFinancialsChartTranscripts

Previous Close

$4.37

52W Range

$2.12 - $4.95

50D Avg

$4.23

200D Avg

$3.27

Market Cap

$181.68M

Avg Vol (3M)

$48.97K

Beta

1.48

Div Yield

-

DMAC Company Profile


DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, develops treatments for neurological and kidney diseases. The company's lead drug candidate is DM199, a recombinant human tissue kallikrein-1 protein, which is in Phase 2 REDUX trial for the treatment of patients with moderate or severe chronic kidney disease caused by Type I or Type II diabetes; and Phase 2/3 REMEDY2 trials for the treatment of patients with acute ischemic stroke. It is also developing DM300 that is in pre-clinical stage for the treatment of inflammatory diseases. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

18

IPO Date

Aug 03, 2012

Website

DMAC Performance


DMAC Financial Summary


Dec 23Dec 22Dec 21
Revenue---
Operating Income$-19.42M$-14.00M$-13.65M
Net Income$-19.38M$-13.68M$-13.59M
EBITDA$-19.42M$-13.98M$-13.62M
Basic EPS-$-0.52$-0.65
Diluted EPS-$-0.52$-0.65

Fiscal year ends in Dec 23 | Currency in USD

Latest Earnings Call Transcripts


Q2 24Aug 11, 24 | 7:31 AM
Q1 24May 09, 24 | 12:00 AM
Q4 23Mar 20, 24 | 4:14 PM

Peer Comparison


TickerCompany
XFORX4 Pharmaceuticals, Inc.
CNTACentessa Pharmaceuticals plc
IOVAIovance Biotherapeutics, Inc.
IKTInhibikase Therapeutics, Inc.
DAWNDay One Biopharmaceuticals, Inc.
SCPHscPharmaceuticals Inc.
HOOKHOOKIPA Pharma Inc.
MCRBSeres Therapeutics, Inc.
TERNTerns Pharmaceuticals, Inc.
ONCYOncolytics Biotech Inc.
MISTMilestone Pharmaceuticals Inc.
LYRALyra Therapeutics, Inc.
LIFEaTyr Pharma, Inc.